Format

Send to

Choose Destination
Br J Clin Pharmacol. 2018 Mar;84(3):510-519. doi: 10.1111/bcp.13467. Epub 2018 Jan 10.

Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Author information

1
Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
2
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
3
DMPK, Genentech, Inc., South San Francisco, CA, USA.
4
Mech-Sense, Department of Gastroenterology & Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg University, Odense, Denmark.
5
Department of Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
6
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
7
Odense Patient Data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.

Abstract

AIM:

The aim of this study was to study potential cytochrome P450 (CYP) induction by dicloxacillin.

METHODS:

We performed an open-label, randomized, two-phase, five-drug clinical pharmacokinetic cocktail crossover study in 12 healthy men with and without pretreatment with 1 g dicloxacillin three times daily for 10 days. Plasma and urine were collected over 24 h and the concentration of all five drugs and their primary metabolites was determined using a liquid chromatography coupled to triple quadrupole mass spectrometry method. Cryopreserved primary human hepatocytes were exposed to dicloxacillin for 48 h and changes in gene expression and the activity of CYP3A4, CYP2C9, CYP2B6 and CYP1A2 were investigated. The activation of nuclear receptors by dicloxacillin was assessed using luciferase assays.

RESULTS:

A total of 10 days of treatment with dicloxacillin resulted in a clinically and statistically significant reduction in the area under the plasma concentration-time curve from 0 to 24 h for omeprazole (CYP2C19) {geometric mean ratio [GMR] [95% confidence interval (CI)]: 0.33 [0.24, 0.45]}, tolbutamide (CYP2C9) [GMR (95% CI): 0.73 (0.65, 0.81)] and midazolam (CYP3A4) [GMR (95% CI): 0.54 (0.41, 0.72)]. Additionally, other relevant pharmacokinetic parameters were affected, indicating the induction of CYP2C- and CYP3A4-mediated metabolism by dicloxacillin. Investigations in primary hepatocytes showed a statistically significant dose-dependent increase in CYP expression and activity by dicloxacillin, caused by activation of the pregnane X receptor.

CONCLUSIONS:

Dicloxacillin is an inducer of CYP2C- and CYP3A-mediated drug metabolism, and we recommend caution when prescribing dicloxacillin to users of drugs with a narrow therapeutic window.

PMID:
29105855
PMCID:
PMC5809358
[Available on 2019-03-01]
DOI:
10.1111/bcp.13467

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center